results of a series of experiments conducted by American researchers on laboratory rats, have allowed the authors of argue that the known drugs for the treatment of erectile dysfunction from the group of inhibitors of phosphodiesterase type 5 (PDE-5), provide the penetration of anti-cancer drugs to brain tumors in laboratory animals.
As you know, between blood and brain tumors is a special biological barrier, a number of characteristics similar to the blood-brain barrier (BBB), existing between the blood and the brain.This barrier provides "filtering" of all substances coming from the bloodstream, thus preventing the penetration of the tumor in many drugs.However, as the data show that the barrier between the blood and tumors, in contrast to the BBB may become permeable by the action of PDE-5 inhibitors, sildenafil ("Viagra"), tadalafil ("Cialis") and vardenafil ("Levitra").
According medportal.ru, scientists from the Medical Center Tsedars-Sinai in Los Angeles, decided to test the practical significan
results showed the following picture: the average length of the animals in the control group who received a placebo, was 32 days, the group receiving only vardenafil - 35 days, but Adriamycin - 42 days.As for those animals who received both drugs, they have this figure was 53 days, and the tumor growth delay was proportional in all these cases.
During their work, the researchers used the dose of vardenafil, which is fully consistent with the therapeutic dosage of erectile dysfunction in men.As noted by the authors of the experiment, the study of side effects and the penetration of adriamycin in the healthy brain tissue were recorded.
In the near future experts plan to conduct a study on people and if results are confirmed, vardenafil will be included in a combination therapy of brain tumors.